<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1659-0775</journal-id>
<journal-title><![CDATA[Odontología Vital]]></journal-title>
<abbrev-journal-title><![CDATA[Odontología Vital]]></abbrev-journal-title>
<issn>1659-0775</issn>
<publisher>
<publisher-name><![CDATA[Universidad Latina de Costa Rica, Facultad de Odontología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1659-07752018000200007</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Relaciones metabólicas de la osteonecrosis de maxilares inducida por bifosfonatos: revisión]]></article-title>
<article-title xml:lang="en"><![CDATA[Metabolic relationships of bisphosphonateinduced osteonecrosis of the jaw: review]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rivera Pérez]]></surname>
<given-names><![CDATA[José Manuel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Latina de Costa Rica  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Costa Rica</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2018</year>
</pub-date>
<numero>29</numero>
<fpage>7</fpage>
<lpage>18</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_arttext&amp;pid=S1659-07752018000200007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_abstract&amp;pid=S1659-07752018000200007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_pdf&amp;pid=S1659-07752018000200007&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen Los BFs son fármacos antirresortivos de elección en el tratamiento de una amplia gama de patologías osteolíticas como osteoporosis, enfermedad de Piaget, hipercalcemia asociada a metástasis ósea y lesiones óseas por mieloma múltiple, entre otras (Adober et ál., 2000). El uso vía oral, VO, de estos medicamentos reporta efectos adversos en el tracto digestivo: náuseas, dolor abdominal, pirosis, úlceras y estenosis esofágica (Jódar et ál., 2002). Desde 2003 también se han relacionado con una exposición ósea en los maxilares denominada osteonecrosis de maxilares inducida por bifosfonatos, ONMIB; particularmente en aplicaciones intravenosas, IV, de mayor biodisponibilidad (Marx et ál., 2003). En pacientes que consumen BFs los tratamientos odontológicos fuertes pueden desencadenar ONMIB (Barquero, 2016). Esta revisión se enfoca en procedimientos de acción de BFs que justifican su acción terapéutica y efectos adversos, entre ellos el desarrollo de osteonecrosis maxilar; también pretende llamar la atención sobre la necesidad de establecer protocolos de abordaje odontológico para pacientes que son tratados con BFs durante largos períodos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Bifosphonates are antiresorptive drugs of choice in the treatment of a wide range of osteolytic pathologies, such as osteoporosis, Piaget&#8217;s disease, hypercalcemia associated with bone metastasis and bone lesions due to multiple myeloma, among others (Adober et ál., 2000). The orally use of these drugs reports adverse effects in the digestive tract: nausea, abdominal pain, heartburn, ulcers and esophageal stenosis (Jódar et ál., 2002). Since 2003, they have also been associated with a bone exposure in the maxilla called bisphosphonate-induced osteonecrosis of jaws; particularly in intravenous application with greater bioavailability (Marx et ál., 2003). In patients who consume BFs aggressive dental treatments can trigger osteonecrosis of the jaw (Barquero, 2016). The present review focuses on mechanisms of action of BFs that justify their therapeutic action and adverse effects, among them the development of osteonecrosis of jaw; also seeks to It also aims to draw attention to the need to establish dental protocols for patients who are treated with BFs for long periods.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Bifosfonatos]]></kwd>
<kwd lng="es"><![CDATA[osteonecrosis maxilar]]></kwd>
<kwd lng="es"><![CDATA[antirresortivos]]></kwd>
<kwd lng="es"><![CDATA[antiangiogénicos]]></kwd>
<kwd lng="en"><![CDATA[Bisphosphonates]]></kwd>
<kwd lng="en"><![CDATA[osteonecrosis of the jaw]]></kwd>
<kwd lng="en"><![CDATA[antiresorptive]]></kwd>
<kwd lng="en"><![CDATA[antiangiogenic]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Adober]]></surname>
<given-names><![CDATA[R. et ál]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Revisión clínica de la utilización de los bifosfonatos]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2000</year>
<volume>24</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>74-82</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arrabal]]></surname>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento de la litiasis renal con bifosfonatos]]></article-title>
<source><![CDATA[Arch. Esp, Urol]]></source>
<year>2007</year>
<volume>60</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>745-54</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Assael]]></surname>
<given-names><![CDATA[L.A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oral bisphosphonates as a cause of biphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies]]></article-title>
<source><![CDATA[J Oral Maxillofac Surg]]></source>
<year>2009</year>
<volume>67</volume>
<page-range>35-43</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barquero]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Osteonecrosis de los maxilares inducida por bifosfonatos]]></article-title>
<source><![CDATA[Odontología Vital]]></source>
<year>2016</year>
<volume>25</volume>
<page-range>5-8</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barret]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Worth]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Bauss]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Epstein]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ibandronate: a clinical pharmacological and pharmacokinetic update]]></article-title>
<source><![CDATA[J Clin Pharmacol]]></source>
<year>2004</year>
<volume>44</volume>
<page-range>951-65</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baynes]]></surname>
<given-names><![CDATA[D.J. N.]]></given-names>
</name>
<name>
<surname><![CDATA[Dominiczak]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Bioquímica médica]]></source>
<year>2015</year>
<edition>Cuarta</edition>
<page-range>343-345 y 582-583</page-range><publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier Saunders]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Birkett]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Farmacocinética fácil]]></source>
<year>2005</year>
<publisher-name><![CDATA[McGraw Hill Interamericana de España]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Borgioli]]></surname>
<given-names><![CDATA[A. et ál]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bisphosphonates-related osteonecrosis of the jaw: clinical and physiopathological considerations]]></article-title>
<source><![CDATA[Ther Clin Risk Manag]]></source>
<year>2009</year>
<volume>5</volume>
<page-range>217-27</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Borissoff]]></surname>
<given-names><![CDATA[J.I. et ál]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The hemostatic system as a modulator of atherosclerosis]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2011</year>
<volume>364</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>1746-60</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Buckley]]></surname>
<given-names><![CDATA[K.A]]></given-names>
</name>
<name>
<surname><![CDATA[Fraser]]></surname>
<given-names><![CDATA[W.D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Receptor activator for nuclear factor kappa B ligand and osteoprotegrin regulators of bone physiology and immune responses/potential therapeutic agents and biochemical markes]]></article-title>
<source><![CDATA[Ann Clin Biochem]]></source>
<year>2002</year>
<volume>39</volume>
<page-range>551-6</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cremers]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Papapoulos]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacology of the bisphosphonates]]></article-title>
<source><![CDATA[Bone]]></source>
<year>2011</year>
<volume>49</volume>
<page-range>42-9</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Doménech]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Tratado general de Biofarmacia y Farmacocinética. Vol. I. LADME. Análisis farmacocinético. Biodisponibilidad y bioequivalencia]]></source>
<year>2013</year>
<publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Editorial Síntesis]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fraga]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hipoxia Tumoral. Papel del factor inducible por hipoxia]]></article-title>
<source><![CDATA[Actas Urol Esp]]></source>
<year>2009</year>
<volume>33</volume>
<numero>9</numero>
<issue>9</issue>
</nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fraser]]></surname>
<given-names><![CDATA[W.D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hyperparathyroidism]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2009</year>
<volume>374</volume>
<page-range>145-58</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García-Ferrer]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MRI of mandibular osteonecrosis secondary to bisphosphonates]]></article-title>
<source><![CDATA[Am J Roent-genol]]></source>
<year>2008</year>
<volume>190</volume>
<page-range>949-55</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[F. R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Osteo-chemonecrosis of the jaws due to bisphosphonate treatments. Update]]></article-title>
<source><![CDATA[Med Oral Patol Oral Cir Bucal]]></source>
<year>2008</year>
<volume>13</volume>
<page-range>318-24</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grunewald]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells]]></article-title>
<source><![CDATA[Cell]]></source>
<year>2006</year>
<volume>124</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>175-89</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harada]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Rodan]]></surname>
<given-names><![CDATA[G.A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Control of osteoblast function and regulation of bone mass]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2003</year>
<volume>423</volume>
<page-range>349-55</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hass]]></surname>
<given-names><![CDATA[E.M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adult intussusceptions]]></article-title>
<source><![CDATA[Am J Surg]]></source>
<year>2003</year>
<volume>186</volume>
<page-range>75-6</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jódar]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Segarra]]></surname>
<given-names><![CDATA[M.C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efectos adversos y contraindicaciones de los bifosfonatos]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Rapado]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz Curiel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Bifosfonatos en las enfermedades del metabolismo óseo y mineral. Fundación Hispana de Osteoporosis y Enfermedades Metabólicas]]></source>
<year>2002</year>
<publisher-name><![CDATA[FHOEMO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Laplante]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Sabatini]]></surname>
<given-names><![CDATA[D.M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[mTOR signaling in growth control and disease]]></article-title>
<source><![CDATA[Cell]]></source>
<year>2012</year>
<volume>149</volume>
<page-range>274-93</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lavandeira]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Un nuevo alerta rojo en odontología: la administración de bifosfonatos]]></article-title>
<source><![CDATA[Rev Asoc Odontol Argent]]></source>
<year>2007</year>
<volume>95</volume>
<page-range>331-4</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lieberman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Marks]]></surname>
<given-names><![CDATA[A.D]]></given-names>
</name>
<name>
<surname><![CDATA[Peet]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Bioquímica médica básica: un enfoque clínico]]></source>
<year>2013</year>
<edition>4</edition>
<publisher-name><![CDATA[Lippincott Williams &amp; Wilkins]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[J.H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bisphosphonates: a review of their pharmacokinetic properties]]></article-title>
<source><![CDATA[Bone]]></source>
<year>1996</year>
<volume>18</volume>
<page-range>75-85</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lomashvili]]></surname>
<given-names><![CDATA[K. A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Regulation of alkaline phosphatase and pyrophosphate hydrolysis: Potential mechanism for uremic vascular calcification]]></article-title>
<source><![CDATA[Kidney Int]]></source>
<year>2008</year>
<volume>73</volume>
<page-range>1024-30</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marx]]></surname>
<given-names><![CDATA[R.E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic]]></article-title>
<source><![CDATA[J. Oral Maxillofac. Surg]]></source>
<year>2003</year>
<volume>61</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1115-7</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mish]]></surname>
<given-names><![CDATA[C.E]]></given-names>
</name>
</person-group>
<source><![CDATA[Implantología contemporánea]]></source>
<year>2009</year>
<volume>6</volume>
<edition>3</edition>
<page-range>71-90</page-range><publisher-loc><![CDATA[Barcelona. España ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morag]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bisphosphonate related osteonecrosis of the jaw: a pictorial review]]></article-title>
<source><![CDATA[Radiographics]]></source>
<year>2009</year>
<volume>29</volume>
<page-range>1971-86</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Murray]]></surname>
<given-names><![CDATA[R. K]]></given-names>
</name>
</person-group>
<source><![CDATA[HARPER. Bioquímica ilustrada]]></source>
<year>2015</year>
<edition>29</edition>
<publisher-name><![CDATA[McGraw Hill]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O&#8217;Reilly]]></surname>
<given-names><![CDATA[M.S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ndostatin an endogenous inhibitor of angiogenesis and tumor growth]]></article-title>
<source><![CDATA[Cell]]></source>
<year>1997</year>
<volume>88</volume>
<page-range>277-85</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Phansih]]></surname>
<given-names><![CDATA[M. K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tumoral calcinosis associated with pyrexia and systemic inflammatory response in a patient hemodialysis: successful treatment using intravenous pamidronate]]></article-title>
<source><![CDATA[Nephrol Dial Transplant]]></source>
<year>2000</year>
<volume>15</volume>
<page-range>1691-3</page-range></nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rachnerd]]></surname>
<given-names><![CDATA[T.D.]]></given-names>
</name>
<name>
<surname><![CDATA[Hofbauer]]></surname>
<given-names><![CDATA[K.S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Osteoporosis: now and the future]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2011</year>
<volume>377</volume>
<page-range>1276-87</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Restrepo]]></surname>
<given-names><![CDATA[C.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Manjarrés]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Controversia en relación con el uso de bifosfonatos en pacientes con enfermedad renal]]></article-title>
<source><![CDATA[Acta Med Colomb]]></source>
<year>2009</year>
<volume>34</volume>
<page-range>176-84</page-range></nlm-citation>
</ref>
<ref id="B34">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Richards]]></surname>
<given-names><![CDATA[J.B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bone mineral density, osteoporosis and osteoporotic fractures: a genome-wide association study]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2008</year>
<volume>371</volume>
<page-range>1505-12</page-range></nlm-citation>
</ref>
<ref id="B35">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roelofs]]></surname>
<given-names><![CDATA[A.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Gordon]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Rogers]]></surname>
<given-names><![CDATA[M. J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Molecular Mechanisms of Action of Bisphosphonates: Current Status]]></article-title>
<source><![CDATA[Clin Cancer Res]]></source>
<year>2006</year>
<volume>12</volume>
<page-range>6222-30</page-range></nlm-citation>
</ref>
<ref id="B36">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Romero Barco]]></surname>
<given-names><![CDATA[C.M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Marcadores bioquímicos en osteoporosis. Utilidad en la práctica clínica]]></article-title>
<source><![CDATA[Reumatol. Clin]]></source>
<year>2012</year>
<volume>8</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>149-52</page-range></nlm-citation>
</ref>
<ref id="B37">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosen]]></surname>
<given-names><![CDATA[L S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[he long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>2003</year>
<volume>98</volume>
<page-range>1735-44</page-range></nlm-citation>
</ref>
<ref id="B38">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rowland]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Tozer]]></surname>
<given-names><![CDATA[T.N]]></given-names>
</name>
</person-group>
<source><![CDATA[Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications]]></source>
<year>2011</year>
<edition>4</edition>
<publisher-loc><![CDATA[Philadelphia ]]></publisher-loc>
<publisher-name><![CDATA[Lippincott Williams and Wilkins]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B39">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Russell]]></surname>
<given-names><![CDATA[R. G.]]></given-names>
</name>
<name>
<surname><![CDATA[Rogers]]></surname>
<given-names><![CDATA[M. J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bisphosphonates: from the laboratory to the clinic and back again]]></article-title>
<source><![CDATA[Bone]]></source>
<year>1999</year>
<volume>25</volume>
<page-range>97-106</page-range></nlm-citation>
</ref>
<ref id="B40">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sartori]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Osteonecrosis del maxilar inferior por bifosfonatos. Presentación de caso]]></article-title>
<source><![CDATA[Rev Argent Radiol]]></source>
<year>2015</year>
<volume>79</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>40-6</page-range></nlm-citation>
</ref>
<ref id="B41">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sosa Henríquez]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Vicente Barrero]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Bocanegra Pérez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Osteonecrosis de los maxilares: nuevas evidencias sobre su etio-patogenia]]></article-title>
<source><![CDATA[Rev Osteoporos Metab Miner]]></source>
<year>2011</year>
<volume>3</volume>
<page-range>5-6</page-range></nlm-citation>
</ref>
<ref id="B42">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Taylor]]></surname>
<given-names><![CDATA[R.C.]]></given-names>
</name>
<name>
<surname><![CDATA[Cullen]]></surname>
<given-names><![CDATA[S.P.]]></given-names>
</name>
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[S.J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Apoptosis: controlled demolition at the cellular level]]></article-title>
<source><![CDATA[Nat Rev Mol Cell Biol]]></source>
<year>2008</year>
<volume>9</volume>
<page-range>231-41</page-range></nlm-citation>
</ref>
<ref id="B43">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Toussaint]]></surname>
<given-names><![CDATA[N.D.]]></given-names>
</name>
<name>
<surname><![CDATA[Elder]]></surname>
<given-names><![CDATA[G.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Kerr]]></surname>
<given-names><![CDATA[P.G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bisphosphonates in Chronic Kidney Disease; Balancing Potential Benefits and Adverse Effects on Bone and Soft Tissue]]></article-title>
<source><![CDATA[Clin J Am Soc Nephrol]]></source>
<year>2009</year>
<volume>4</volume>
<page-range>221-33</page-range></nlm-citation>
</ref>
<ref id="B44">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trouvin]]></surname>
<given-names><![CDATA[A.P.]]></given-names>
</name>
<name>
<surname><![CDATA[Goëb]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Receptor activator of nuclear factor-&#954;B ligand and osteoprotegerin: maintaining the balance to prevent bone loss]]></article-title>
<source><![CDATA[Clinical Interventions in Aging]]></source>
<year>2010</year>
<volume>5</volume>
<page-range>345-54</page-range></nlm-citation>
</ref>
<ref id="B45">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vink]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HIF-1 alpha expression is associated with an atheromatous inflammatory plaque phenotype and upregulated in activated macrophages]]></article-title>
<source><![CDATA[Atherosclerosis]]></source>
<year>2007</year>
<volume>195</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>69-75</page-range></nlm-citation>
</ref>
<ref id="B46">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wierna]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Osteonecrosis maxilar postextracción dentaria en pacientes bajo tratamiento con bifosfonatos: presentación de 2 casos clínicos]]></article-title>
<source><![CDATA[Rev Circ Argent Odontol]]></source>
<year>2009</year>
<volume>66</volume>
<page-range>14-8</page-range></nlm-citation>
</ref>
<ref id="B47">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ylitalo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bisphosphonates and atherosclerosis]]></article-title>
<source><![CDATA[Gen Pharmacol]]></source>
<year>2000</year>
<volume>35</volume>
<page-range>287-896</page-range></nlm-citation>
</ref>
<ref id="B48">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Young]]></surname>
<given-names><![CDATA[S.G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Targeting Protein Prenylation in Progeria]]></article-title>
<source><![CDATA[Sci Transl Med]]></source>
<year>2013</year>
<volume>2</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>171-4</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
